Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

ClinicalTrials.gov ID: NCT02718326

Public ClinicalTrials.gov record NCT02718326. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR). The secondary objectives of the study are: * To characterize the safety of IVT aflibercept in patients with moderately severe to severe NPDR * To determine if IVT aflibercept will prevent the worsening of diabetic retinopathy and reduce the incidence of DME * To determine the anatomic effects of IVT aflibercept in patients with moderately severe to severe NPDR

Study identification

NCT ID
NCT02718326
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
402 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 28, 2016
Primary completion
Aug 5, 2018
Completion
Jul 15, 2019
Last update posted
Jul 29, 2020

2016 – 2019

United States locations

U.S. sites
71
U.S. states
28
U.S. cities
66
Facility City State ZIP Site status
Regeneron Study Site Phoenix Arizona 85020
Regeneron Study Site Tucson Arizona 85704
Regeneron Study Site Arcadia California 91007
Regeneron Study Site Beverly Hills California 90211
Regeneron Study Site Encino California 91436
Regeneron Study Site Fullerton California 92835
Regeneron Study Site La Jolla California 92093
Regeneron Study Site Mountain View California 94040
Regeneron Study Site Oakland California 94609
Regeneron Study Site Oceanside California 92056
Regeneron Study Site Sacramento California 95841
Regeneron Study Site Colorado Springs Colorado 80909
Regeneron Study Site Golden Colorado 80401
Regeneron Study Site New London Connecticut 06320
Regeneron Study Site Altamonte Springs Florida 32701
Regeneron Study Site Deerfield Beach Florida 33064
Regeneron Study Site Fort Myers Florida 33912
Regeneron Study Site Lakeland Florida 33805
Regeneron Study Site Largo Florida 33770
Regeneron Study Site Melbourne Florida 32901
Regeneron Study Site Miami Florida 33126
Regeneron Study Site Miami Florida 33143
Regeneron Study Site Orlando Florida 32806
Regeneron Study Site Plantation Florida 33324
Regeneron Study Site Tallahassee Florida 32308
Regeneron Study Site Tampa Florida 33612
Regeneron Study Site Winter Haven Florida 33880
Regeneron Study Ssites Marietta Georgia 30060
Regeneron study Site Tucker Georgia 30084
Regeneron Study Site Chicago Illinois 60612
Regeneron Study Site Oak Forest Illinois 60452
Regeneron Study Site Indianapolis Indiana 46290
Regeneron Study Site New Albany Indiana 47150
Regeneron Study Site Lexington Kentucky 40509
Regeneron Study Site Baltimore Maryland 21204
Regeneron Study Siste Baltimore Maryland 21209
Regeneron Study Site Baltimore Maryland 21287
Regeneron Study Site Hagerstown Maryland 21740
Regeneron Study Site Boston Massachusetts 02114
Regeneron Study Site Henderson Nevada 89052
Regeneron Study Site Bloomfield New Jersey 07003
Regeneron Study Site Albuquerque New Mexico 87109
Regeneron Study Site Asheville North Carolina 28803
Regeneron Study Site Charlotte North Carolina 28210
Regeneron Study Site Columbus Ohio 43212
Regeneron Study Site Oklahoma City Oklahoma 73104
Regeneron Study Site Medford Oregon 97504
Regeneron Study Site Kingston Pennsylvania 18704
Regeneron Study Site Philadelphia Pennsylvania 19107
Regeneron Study Site Florence South Carolina 29501
Regeneron Study Site Ladson South Carolina 29456
Regeneron Study Site West Columbia South Carolina 29169
Regeneron Study Site Rapid City South Dakota 57701
Regeneron Study Site Chattanooga Tennessee 37421
Regeneron Study Site Germantown Tennessee 38138
Regeneron Study Site Nashville Tennessee 37203
Regeneron Study Site Nashville Tennessee 37232
Regeneron Study Site Abilene Texas 79606
Regeneron Study Site 1 Austin Texas 78705
Regeneron Study Site 2 Austin Texas 78705
Regeneron Study Site Dallas Texas 75231
Regeneron Study Site Harlingen Texas 78559
Regeneron Study Site Houston Texas 77030
Regeneron Study Site San Antonio Texas 78240
Regeneron Study Site The Woodlands Texas 77384
Regeneron Study Site Willow Park Texas 76087
Regeneron Study Site Salt Lake City Utah 84132
Regeneron Study Site Burlington Vermont 05401
Regeneron Study Site Fairfax Virginia 22031
Regeneron Study Site Spokane Washington 99204
Regeneron Study Site Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02718326, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 29, 2020 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02718326 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →